Finance

Beta
Lists
ATRC:NASDAQ
AtriCure Inc
$30.18
+7.29%
(+2.05) 1D
$30.18
-0.00% (-0.00050)
After hours
Closed: Jun 26, 4:00:02 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ATRC...
Open
$28.30
High
$30.38
Low
$28.29
Mkt. cap
1.53B
Avg. vol.
818.75K
Volume
2.77M
52-wk high
$43.18
52-wk low
$25.37
EPS
-$0.10
Beta
1.26
Shares outstanding
50.64M
No. of employees
1K
Open
$28.30
High
$30.38
Low
$28.29
Mkt. cap
1.53B
Avg. vol.
818.75K
Volume
2.77M
52-wk high
$43.18
52-wk low
$25.37
EPS
-$0.10
Beta
1.26
Shares outstanding
50.64M
No. of employees
1K
News stories
From sources across the web
About AtriCure Inc
CEOMichael H Carrel | Michael H Carrel
Employees1.35K
FoundedNov 2000
HeadquartersMason, Ohio, United States
SectorMedical device
Websiteatricure.com
Analyst ratings
Based on 5 analysts giving stock ratings to ATRC in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for ATRC in the last 3 months.
Highest
Current $30.18
$55.00 (+82.24%)
Average
$49.00 (+62.36%)
Lowest
$45.00 (+49.11%)
Analyst
Recommendation
Action
Price target
Projected
Date
Marie Thibault
BTIG
Buy
Reiterated
$45.00
+49.1%
06/15/2026
William Plovanic
Canaccord Genuity
Buy
Maintained
$55.00
+82.2%
05/06/2026
Rick Wise
Stifel Nicolaus
Buy
Maintained
$50.00
+65.7%
05/06/2026
Matthew O'Brien
Piper Sandler
Buy
Reiterated
$50.00
+65.7%
05/06/2026
Michael Matson
Needham
Buy
Reiterated
$45.00
+49.1%
05/06/2026
Danielle Antalffy
UBS
Buy
Maintained
$55.00
+82.2%
02/18/2026
Suraj Kalia
Oppenheimer
Hold
Downgraded
-
-
02/18/2026
Daniel Stauder
Citizens JMP
Buy
Maintained
$52.00
+72.3%
02/18/2026
Lilia-Celine (Lily) Lozada
J.P. Morgan
Hold
Downgraded
$36.00
+19.3%
02/10/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
136.14M
134.27M
140.50M
141.25M
Cost of goods sold
34.66M
32.94M
35.16M
31.94M
Cost of revenue
34.66M
32.94M
35.16M
31.94M
Research and development expenses
29.28M
22.89M
24.50M
24.24M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
78.39M
78.23M
78.34M
84.55M
Operating expense
107.67M
101.12M
102.85M
108.78M
Total operating expenses
142.33M
134.06M
138.01M
140.72M
Operating income
-6.19M
208.00K
2.49M
526.00K
Other non operating income
61.00K
9.00K
-641.00K
-37.00K
EBT including unusual items
-5.93M
-86.00K
2.36M
394.00K
EBT excluding unusual items
-5.93M
-86.00K
2.36M
394.00K
Income tax expense
261.00K
181.00K
604.00K
286.00K
Effective tax rate
-4.40%
-210.47%
25.59%
72.59%
Other operating expenses
-
-
-
-
Net income
-6.19M
-267.00K
1.76M
108.00K
Net profit margin
-4.55%
-0.20%
1.25%
0.08%
Earnings per share
-0.02
-0.01
0.06
-
Interest and investment income
941.00K
1.16M
1.33M
1.24M
Interest expense
-1.49M
-1.47M
-1.50M
-1.34M
Net interest expenses
-549.00K
-303.00K
-173.00K
-95.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-1.02M
5.38M
7.60M
5.80M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of ATRC
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer